Alvimopan

From Wikipedia, the free encyclopedia

Alvimopan
Systematic (IUPAC) name
2-([(2S)-2-([(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl) -3-phenylpropanoyl]amino)acetic acid
Identifiers
CAS number 156053-89-3
ATC code  ?
PubChem 5488548
Chemical data
Formula C25H32N2O4 
Mol. mass 424.53 g/mol
SMILES eMolecules & PubChem
Synonyms Alvimopan, Entereg
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes Oral

Alvimopan (Entereg) is a drug which behaves as a peripherally acting μ-opioid antagonist. With limited ability to cross the blood-brain barrier, many of the undesirable side-effects of the opioid agonists such as constipation are minimized without affecting analgesia or precipitating withdrawals.[1][2] The Food and Drug Administration reviewed the safety and efficacy data for alvimopan and approved its use in May 2008.[3]

[edit] References

  1. ^ Neary P, Delaney P (2005). "Alvimopan". Expert Opin Investig Drugs 14 (4): 479–88. doi:10.1517/13543784.14.4.479. PMID 15882122. 
  2. ^ Schmidt WK (2001). "Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist". Am J Surg 182 (5A Supp): 27S–38S. doi:10.1016/S0002-9610(01)00784-X. PMID 11755894. 
  3. ^ FDA press release - FDA Approves Entereg to Help Restore Bowel Function Following Surgery